Takeda Pharmaceutical Company Limited (”Takeda”) announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary received on June 26 (U.S. time) a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Companys New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP4) inhibitor [...]